Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas (NCT04620187)
A Phase II Study of Adjuvant Ado-trastuzumab Emtansine (T-DM1) in HER2-positive Salivary Gland Carcinomas
🩺 Plain-English Summary (8th-Grade Level)
This research is being done to see how safe and effective the use of the study drug Ado-trastuzumab (T) emtansine (DM1), T-DM1, and standard of care chemoradiation are when used together in treating HER2-positive salivary gland cancer. It will also examine the effectiveness of study drug Ado-trastuzumab (T) emtansine (DM1) on cancer recurrence.
Who can join: Review the eligibility criteria below.
Location: Winship Cancer Institute, Emory University — Atlanta, Georgia
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- Winship Cancer Institute, Emory University — Atlanta, Georgia
- University of Chicago — Chicago, Illinois
- Brigham and Women's Hospital — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
- Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey
- Memorial Sloan Kettering Bergen — Montvale, New Jersey
- Memorial Sloan Kettering Commack — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Memorial Sloan Kettering Nassau — Uniondale, New York
- University of Washington Medical Center — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (617) 632-3090
Email: glenn_hanna@dfci.harvard.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Salivary Gland Cancer
- 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma — Boston, Massachusetts
- Amivantamab in Adenoid Cystic Carcinoma — La Jolla, California
- Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers — Boston, Massachusetts
- A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers — Boston, Massachusetts
Explore by condition: All Salivary Gland Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.